Related Experiment Video
Updated: Aug 7, 2026

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
Published on: March 30, 2015
Cost-effectiveness and reimbursement issues in renal cell carcinoma
1Joint Section of Hematology/Oncology, University of Chicago Medical School, IL 60637.
Abstract:
The increasing focus on cost-effectiveness in all cancer care and the decision of many third-party payers to deny funding for investigational therapy is of particular concern in metastatic renal cell carcinoma. There is as yet no effective standard treatment for this disease; surgery, radiotherapy, and chemotherapy have all proved inadequate. The use of "investigational" therapy with biologic response modifiers, such as alpha interferon and interleukin-2, however, has shown promise. Investigational therapy, therefore, actually represents state-of-the-art treatment that offers the patient the best chance for increased survival, tumor regression, and improved quality of life. Under the current method of insurance reimbursement, however, investigational research is threatened despite the numerous reasons that such treatment is both cost-effective and therapeutically sound.
Insights
Investigational biologic response modifiers offer promising, cost-effective treatments for metastatic renal cell carcinoma. Current reimbursement policies threaten access to this state-of-the-art, life-improving cancer care.
Area of Science:
- Oncology
- Cancer Research
- Immunotherapy
Background:
- Metastatic renal cell carcinoma lacks effective standard treatments.
- Traditional therapies like surgery, radiotherapy, and chemotherapy are inadequate.
- Increasing focus on cost-effectiveness impacts cancer care funding.
Purpose of the Study:
- To highlight the promise of investigational therapies for metastatic renal cell carcinoma.
- To address concerns regarding third-party payer denials for investigational treatments.
- To advocate for the cost-effectiveness and therapeutic value of biologic response modifiers.
Main Methods:
- Review of current treatment landscape for metastatic renal cell carcinoma.
- Analysis of the efficacy of biologic response modifiers (e.g., alpha interferon, interleukin-2).
- Evaluation of the cost-effectiveness and reimbursement challenges for investigational therapies.
Main Results:
- Biologic response modifiers show promise in improving survival and quality of life.
- Investigational therapies represent state-of-the-art treatment options.
- Current reimbursement practices pose a threat to vital cancer research.
Conclusions:
- Investigational therapies, particularly biologic response modifiers, offer significant benefits for metastatic renal cell carcinoma patients.
- These treatments are therapeutically sound and potentially cost-effective.
- Reimbursement policies must be re-evaluated to support access to advanced cancer care.
More Related Videos
Related Concept Videos
Radiological Investigation I: X-ray and CT
Kidney Transplant III: Nursing Management
Imaging Studies III: Computed Tomography
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Imaging Studies VII: Vascular Imaging

